Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: NFLX AMZN IBB TSLA ILMN SLXP Z AMGN COST GMCR SBAC GILD WDC AAPL SNDK CELG VRTX MNST EXPE
Nyse: ACT LNKD V IVV IBM GS LMT AGN TWC CMI MMM XEC APD CVX BA GD MON WLP APC UTX
New Highs: NFLX EQIX IVV PSA LMT SPG COO AVB FLT NOC GD BXP FFIV ECL UHS UNP EXP EW WLK PEP

The Hot Industries

Aerospace/Defense Products & Services 2
Railroads 1
Hospitals 1

The Hot Sectors

Financial 4
Industrial Goods 4
Services 3

CELG Stock Chart


CELG
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

5,100
Monthly

Website:

http://www.celgene.com

CELG Celgene Corporation

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

favicon

Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog

21 Aug 2014, 4:12 pmBristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
favicon

Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments

21 Aug 2014, 2:20 pmBristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
favicon

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus

20 Aug 2014, 8:08 amLast week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
favicon

Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog

19 Aug 2014, 12:13 pmBiogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
favicon

3 Reasons Celgene Corporation's Stock Could Rise

18 Aug 2014, 12:11 pm3 Reasons Celgene Corporation's Stock Could Rise
favicon

Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver

5 Aug 2014, 8:23 amCHICAGO, Aug. 5, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CELG, WB, SPWR, and TWX. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note:...
favicon

Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales

25 Jul 2014, 12:45 pmCelgene (CELG) reported higher than expected earnings on strong revenues.
favicon

Will This Price Target Increase Help Celgene (CELG) Stock Today?

25 Jul 2014, 7:31 amNEW YORK (TheStreet) -- Credit Suisse increased its price target on Celgene  to $113, increased its estimates through 2016 and set an "outperform" rating. The firm cited the company's new guidance as the reason for the move. The stock was down 0.39% to $85.85 in pre-market trading on Friday. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a ...
favicon

Celgene (CELG) Stock Falls After Mixed Second-Quarter Earnings

24 Jul 2014, 7:43 am(Update 9:45 a.m.): Updated with conference call information and stock price. NEW YORK (TheStreet) -- Celgene  fell 2.01% to $87.33 in early morning trading on Thursday after the biotechnology company reported mixed second-quarter results. Celgene reported a year-over-year increase in net profit to $597.8 million, or 72 cents a share, from $478.1 million, or 56 cents a share. Profit excluding ...
favicon

Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG

24 Jul 2014, 4:13 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Wednesday's Mad Money on CNBC: PEP data by YCharts Pepsico : Looking for a winner in the consumer packaged-goods space? Cramer said Pepsico remains a favorite in the sector. \CELG data by YCharts Celgene ...